INTEGRA LIFESCIENCES HOLDINGS CORP 8-K

What Happened

• Integra LifeSciences Holdings Corp. announced amendments to its accounts receivable securitization facility originally entered into on December 18, 2018. On April 10, 2026 the company executed Amendment No. 8 to the Receivables Financing Agreement (RFA) and Amendment No. 1 to the Purchase and Sale Agreement (PSA).
• The RFA Amendment extends the scheduled termination date of the A/R Facility to April 10, 2029 and updates certain customary representations, covenants and concentration limits. The PSA Amendment updates customary representations and covenants under the PSA. The amendments were disclosed in an 8‑K filed April 15, 2026; full amendment documents will be filed as exhibits to Integra’s Form 10‑Q for the quarter ended March 31, 2026.

Key Details

• Original facility size: $150 million (A/R securitization facility established Dec. 18, 2018).
• Amendment execution date: April 10, 2026; 8‑K filed April 15, 2026.
• Parties include borrower Integra Receivables LLC, servicer Integra LifeSciences Sales LLC, PNC Bank (Administrative Agent and Committed Lender), The Bank of Nova Scotia (Committed Lender and Group Agent), and PNC Capital Markets LLC (Structuring Agent).
• RFA Amendment: extends termination to April 10, 2029 and adjusts customary reps/covenants and concentration limits; PSA Amendment: updates customary reps/covenants.

Why It Matters

• The amendment preserves Integra’s access to a committed source of liquidity and funding tied to its accounts receivable through 2029, which supports working capital and reduces near‑term pressure on the company’s senior credit revolver.
• Changes to representations, covenants and concentration limits are standard but can affect the size of the borrowing base and the company’s flexibility to finance receivables; investors should review the filed amendment exhibits in the 10‑Q when available for full details.